Q32 Bio Inc.

QTTB Healthcare Biotechnology

Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million.

EPS
+43.6%
Free cash flow
+71.1%
Total debt
−35.6%

Quarter to June 2026, against a year earlier

9.25 0.40 +4.52%
Market cap
$263.5M
P/E
3.1×
Fwd P/E
−6.2×
Dividend yield
—
F-score
n/a
Altman Z
−0.78
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00 — 1.43
Piotroski F-Score
— — — — 2 3 1 — — —
Altman Z-Score
— — 5.77 8.97 2.13 (0.28) (2.85) (8.70) — (0.78)
P/S ratio
— — 120.05 523.70 191.96 5.93 21.49 0.00 — 0.00
P/FCF ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
Altman Z″-Score (non-manufacturers)
— — 5.57 6.11 0.56 0.07 (1.79) (18.45) — (2.11)
P/Operating CF
— — (79.08) (33.13) (44.67) (6.62) (2.53) (0.35) — (6.61)
P/B ratio
— — 3.25 3.38 2.65 1.19 0.39 0.00 — 0.97
EV/Sales
— — 79.70 366.20 117.21 2.04 (23.88) (3.34) — (0.34)
EV/EBITDA
— — 0.00 0.00 0.00 0.00 0.57 0.00 — 0.00
EV/FCF
— — (6.28) (5.39) (3.23) (0.62) 0.67 (1.19) — (0.08)
Current Ratio
1.88 14.85 9.84 21.54 9.69 11.14 8.02 2.04 4.97 4.85
Net Debt/EBITDA
1.17 4.48 3.66 2.53 1.65 1.52 1.09 (0.39) 1.00 (2.21)
Debt/Equity
0.00 0.00 0.00 0.00 0.08 0.14 0.17 (0.62) 2.23 0.23
ROE
32.61% 121.55% (70.84%) (45.69%) (56.63%) (52.38%) (2.88%) 2,174.51% 53.86% 125.06%
ROA
(10.61%) (39.53%) (28.03%) (36.48%) (44.82%) (40.28%) (2.27%) (39.01%) (68.49%) 38.70%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (159.02%) (256.87%) 0.00% 0.00% 308.43%
Return on Tangible Assets
(106.37%) (23.82%) (23.67%) (35.00%) (55.02%) (54.12%) (3.14%) (327.92%) (71.48%) 66.74%
Average Days of Receivables
0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00
Earnings Yield
— — (24.45%) (11.92%) (24.78%) (46.40%) (7.49%) (1,417.73%) — 69.88%
Free Cash Flow Yield
— — (10.57%) (12.97%) (18.91%) (55.69%) (166.75%) (492.77%) — (65.18%)
Free Cash Flow per Share
(99.09) 32.81 (42.52) (48.33) (38.42) (36.48) (36.02) (53.51) (7.27) (2.16)
Book value per Share
70.96 713.41 123.69 110.39 76.78 55.19 55.77 (204.74) 0.61 3.42
Free Cash Flow
(10.47) 4.52 (67.50) (113.19) (98.06) (112.15) (114.95) (18.68) (67.79) (26.54)
EV/EBIT
— — 0.00 0.00 0.00 0.00 0.57 0.00 — 0.13
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026